Goal PTT for DVT Patients on Heparin Therapy

Therapeutic Range and Monitoring

The American College of Cardiology recommends that the therapeutic aPTT range for patients with deep vein thrombosis (DVT) on unfractionated heparin therapy should be 60-85 seconds, which corresponds to a plasma heparin level of 0.2 to 0.4 U/mL by protamine titration or 0.35 to 0.7 U/mL in terms of anti-factor Xa activity, with a strength of evidence based on clinical trials 1, 2
Patients with subtherapeutic aPTT values (<50 seconds) have a 15-fold increased risk of recurrent venous thromboembolism, according to the American Heart Association 3
aPTT should be measured 6 hours after the initial bolus dose of heparin, and the continuous IV dose should be adjusted according to the result, as recommended by the American College of Chest Physicians 4
Despite its limitations, aPTT remains the most convenient and most frequently used method for monitoring the anticoagulant response to heparin, with a moderate level of evidence 2

Initial dosing for DVT treatment typically involves an 80 U/kg bolus, followed by 18 U/kg/h continuous infusion, based on guidelines from the American College of Cardiology 3
Dose adjustments should follow established nomograms based on aPTT results, with the following protocol:
- aPTT <35 seconds: 80 U/kg bolus, then increase infusion by 4 U/kg/h 3
- aPTT 35-45 seconds: 40 U/kg bolus, then increase infusion by 2 U/kg/h 3
- aPTT 46-70 seconds: No change 3
- aPTT 71-90 seconds: Decrease infusion rate by 2 U/kg/h 2
- aPTT >90 seconds: Interrupt infusion for 1 hour, then decrease rate by 3 U/kg/h 3

The therapeutic range must be adapted to the responsiveness of the specific aPTT reagent used by your laboratory, as different reagents have varying sensitivities to heparin, with a high level of evidence 2
Pharmacokinetic limitations of heparin include variable anticoagulant response due to binding to plasma proteins, proteins released from platelets, and endothelial cells, according to the American Society of Hematology 4
Heparin resistance may occur in some patients, requiring higher doses to achieve therapeutic aPTT levels, with a moderate level of evidence 4

Failing to recognize that the therapeutic range varies with the responsiveness of the aPTT reagent to heparin, with a high level of evidence 2
Not monitoring aPTT at appropriate intervals (6 hours after bolus dose and then daily), as recommended by the American College of Chest Physicians 4
Overlooking the need to adjust dosing regimens when heparin is combined with thrombolytic therapy or platelet GP IIb/IIIa antagonists, with a moderate level of evidence 4
Ignoring the potential for heparin-induced thrombocytopenia (HIT), which requires periodic monitoring of platelet counts throughout therapy, with a high level of evidence 4
Excessive anticoagulation (aPTT >90 seconds) increases bleeding risk without providing additional antithrombotic benefit, according to the American Heart Association 3

The American College of Cardiology recommends that low molecular weight heparin (LMWH) is now often preferred over unfractionated heparin for DVT treatment due to more predictable pharmacokinetics and reduced need for monitoring, with a high level of evidence 6
For patients transitioning to warfarin, heparin should overlap with warfarin for at least 5-7 days until the INR is in the therapeutic range (2.0-3.0) for 2 consecutive days, as recommended by the American College of Chest Physicians 6